Journal
LEUKEMIA & LYMPHOMA
Volume 48, Issue 12, Pages 2330-2337Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/10428190701647887
Keywords
aspirin; lenalidomide; multiple myeloma; thalidomide; thrombosis
Categories
Funding
- NCI NIH HHS [CA109260-01] Funding Source: Medline
- NATIONAL CANCER INSTITUTE [K23CA109260] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Multiple myeloma (MM) patients have a propensity for thromboembolic events (TE), and treatment with thalidomide/dexamethasone or lenalidomide/dexamethasone increases this risk. This report describes the use of low-dose aspirin (81 mg) as primary thromboprophylaxis in three series of MM patients receiving thalidomide or lenalidomide with other drugs. In the first regimen (clarithromycin, thalidomide, dexamethasone), initiation of low-dose aspirin negated the occurrence of any further TE. In a second study, prophylactic aspirin given with thalidomide/ dexamethasone resulted in a rate of TE similar to that seen with dexamethasone alone (without aspirin). A third study (n 72) evaluated thrombosis rates with aspirin and a lenalidomide-containing regimen (clarithromycin, lenalidomide, dexamethasone). Of nine occurrences of thromboembolism, five were associated with aspirin interruption or poor compliance. Low-dose aspirin appears to reduce the incidence of thrombosis with these regimens. Routine use of aspirin as antithrombotic prophylaxis in MM patients receiving immunomodulatory drugs with corticosteroids is warranted.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available